,Canonical_Smiles,drug_name,drug_type,Label
0,CC(=O)C1CCC2C3CC=C4CC(O)CCC4(C)C3CCC12C,Pregnenolone,2D6-Substrate,negative
1,COC(=O)N[C@H](C(=O)N[C@@H](Cc1ccccc1)[C@@H](O)CN(Cc1ccc(-c2ccccn2)cc1)NC(=O)[C@@H](NC(=O)OC)C(C)(C)C)C(C)(C)C,Atazanavir,P450_HFLA-Inhibitor,positive
2,C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]2(C)[C@@]1(O)C(=O)CO,Dexamethasone,4A11-Inducer,negative
3,COc1c2ccoc2cc2oc(=O)ccc12,Bergapten,N_acetyltransferase-Inhibitor,negative
4,CSCC[C@H](N)C(=O)O,Methionine,GST-Inducer,negative
5,CO[C@H]1C[C@@H]2CC[C@@H](C)[C@@](O)(O2)C(=O)C(=O)N2CCCC[C@H]2C(=O)O[C@H]([C@H](C)C[C@@H]2CC[C@@H](OCCO)[C@H](OC)C2)CC(=O)[C@H](C)C=C(C)[C@@H](O)[C@@H](OC)C(=O)[C@H](C)C[C@H](C)C=CC=CC=C1C,Everolimus,-,negative
6,C=CC#N,acrylonitrile,2E1-Substrate,negative
7,N=C(N)NCCN1CCCCCCC1,Guanethidine,3A4-Inducer,negative
8,COc1ccc(OC(F)(F)F)cc1CN,cp_677_623,2E1-Substrate,negative
9,C[C@]12CC[C@@H]3c4ccc(O)cc4C[C@@H](CCCCCCCCCS(=O)CCCC(F)(F)C(F)(F)F)[C@H]3[C@@H]1CC[C@@H]2O,Fulvestrant,3A4-Substrate,negative
10,C[C@]12C[C@@H]3C[C@](C)(C1)C[C@@](N)(C3)C2,Memantine,2D6-Inhibitor,negative
11,O=C(O)CC[C@H]1[C@@H](NS(=O)(=O)c2ccccc2)C2CC[C@@H]1C2,tetranor,2C9-Substrate,negative
12,COCc1c(C(C)C)nc(C(C)C)c(/C=C/[C@@H](O)C[C@@H](O)CC(=O)O)c1-c1ccc(F)cc1,cerivastatin,3A4-Substrate,negative
13,O=NN(CCCl)C(=O)NC1CCCCC1,Lomustine,2D6-Substrate,negative
14,OO,Hydrogen Peroxide,GST-Inhibitor,negative
15,CC(C)[C@]12CC(=O)[C@@H](C)[C@H]1C2,beta_thujone,3A4-Substrate,negative
16,C=CC(=C)C,isoprene,2E1-Substrate,negative
17,Cc1c(O)cccc1C(=O)N[C@@H](CSc1ccccc1)[C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C,Nelfinavir,P450_HFLA-Inhibitor,positive
18,CN1C(C(=O)Nc2ccccn2)=C(O)c2sc(Cl)cc2S1(=O)=O,Lornoxicam,-,negative
19,Nc1ccc(S(=O)(=O)c2ccc(N)cc2)cc1,Dapsone,CP2CI-Substrate,negative
20,NC(=O)OCC(COC(N)=O)c1ccccc1,Felbamate,2E1-Substrate,negative
21,CCCCCN(C)N=O,N_amyl_N_methyl_nitrosamine,2E1-Substrate,negative
22,C=CCN,Trastuzumab,19A-Inhibitor,negative
23,COc1cc(NS(C)(=O)=O)ccc1Nc1c2ccccc2nc2ccccc12,Amsacrine,2D6-Substrate,negative
24,Oc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,bis_OH_methoxychlor,3A4-Substrate,negative
25,CC(O)(CC(=O)O)CC(=O)O,Meglutol,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
26,CC(=O)OCC(CCn1cnc2cnc(N)nc21)COC(C)=O,Famciclovir,3A4-Substrate,negative
27,CC(C)(C)NC[C@H](O)c1cc(Cl)c(N)c(Cl)c1,Clenbuterol,1A2-Substrate,negative
28,NS(=O)(=O)c1cc2c(cc1Cl)NCNS2(=O)=O,Hydrochlorothiazide,Solute_carrier_family_12_member_1-Inducer,negative
29,CCC(c1ccc(O)c(F)c1)C(C)c1ccc(O)c(F)c1,Bifluranol,-,negative
30,N#C[C@@H]1C[C@@H]2C[C@@H]2N1C(=O)[C@@H](N)C12CC3CC(CC(O)(C3)C1)C2,Saxagliptin,3A4-Substrate,negative
31,O=C(O)CCCC[C@@H]1CCSS1,Tioctic Acid,GST-Inducer,negative
32,CCc1cc2c(s1)N(C)C(=O)CN=C2c1ccccc1Cl,Clotiazepam,CP2CI-Substrate,negative
33,CC(C)c1nc(N(C)S(C)(=O)=O)nc(-c2ccc(F)cc2)c1C=C[C@H](O)C[C@@H](O)CC(=O)O,Rosuvastatin,Sodiumbile_acid_cotransporter-Substrate,negative
34,CC(C)NNC(=O)c1ccncc1,Iproniazide,N_acetyltransferase-Inhibitor,negative
35,COC1=CC(=O)OC1C(O)c1ccccc1Cl,Losigamone,-,negative
36,CN1CCCCC1CCN1c2ccccc2Sc2ccc(S(C)=O)cc21,mesoridazine,2D6-Substrate,negative
37,COc1cc(CNC(=O)CCCCC=CC(C)C)ccc1O,Capsaicin,2E1-Substrate,negative
38,CN1C(C(=O)Nc2ccccn2)=C(O)c2ccccc2S1(=O)=O,Piroxicam,-,negative
39,COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@@H]1c1cccc([N+](=O)[O-])c1,Nimodipine,-,negative
40,Clc1ccc([C@@H](Cn2ccnc2)OCc2csc3c(Cl)cccc23)c(Cl)c1,Sertaconazole,Sterol_14_alpha_demethylase_Lanosterol_14_alpha_demethylase-Inhibitor,negative
41,C/C=C/c1ccccc1,trans_phenylpropene,2E1-Substrate,negative
42,COC(=O)Nc1nc2cc(Sc3ccccc3)ccc2[nH]1,Fenbendazole,1A2-Inducer,negative
43,CC1=C(/C=C/C(C)=C/C=C/C(C)=C/CO)C(C)(C)CCC1,retinol,2D6-Substrate,negative
44,CC[C@H]1NC(=O)[C@@H](NC(=O)c2ncccc2O)[C@@H](C)OC(=O)[C@H](c2ccccc2)NC(=O)[C@H]2CC(=O)[C@H](CS[C@@H]3CN4CCC3CC4)CN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@@H]2CCCN2C1=O,Quinupristin/dalfopristin,3A4-Inhibitor,negative
45,CC(C)OC(=O)CCCC=CC[C@H]1[C@@H](O)C[C@@H](O)[C@@H]1CC[C@@H](O)CCc1ccccc1,Latanoprost,Solute_carrier_organic_anion_transporter_family_member_2A1-Inhibitor,negative
46,CC(=O)[C@@]1(C)CC[C@H]2[C@H]3C=C(C)C4=CC(=O)CC[C@@]4(C)[C@@H]3CC[C@]21C,Medrogestone,3A4-Substrate,negative
47,CCC(=O)O[C@]1(C(=O)SCF)[C@H](C)C[C@H]2[C@@H]3C[C@H](F)C4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@@]21C,Fluticasone,-,negative
48,CC[C@H](C)n1ncn(-c2ccc(N3CCN(c4ccc(OC[C@H]5CO[C@](Cn6cncn6)(c6ccc(Cl)cc6Cl)O5)cc4)CC3)cc2)c1=O,Itraconazole,19A-Inhibitor,negative
49,C=C1/C(=C\C=C2/CCC[C@@]3(C)[C@H]2CC[C@@H]3[C@H](C)/C=C/[C@H](C)C(C)C)C[C@@H](O)C[C@@H]1O,1_alpha_hydroxy_vitamin_D2,3A4-Substrate,negative
50,O=C(Cn1c(=O)sc2ccc(Cl)cc21)N1CCN(CCO)CC1,Tiaramide,-,negative
51,C[C@H](NCCc1ccc(O)cc1)[C@H](O)c1ccc(O)cc1,Ritodrine,SUL-Substrate,negative
52,COc1cccc([C@@]2(O)CCCC[C@@H]2CN(C)C)c1,Tramadol,2D6-Inhibitor,negative
53,C[C@@]12CC[C@H]3c4ccc(OC(=O)N(CCCl)CCCl)cc4CC[C@@H]3[C@@H]1CC[C@@H]2O,Estramustine,3A4-Substrate,negative
54,Nc1ccc(C(=O)O)c(O)c1,Aminosalicylic Acid,Sodium_coupled_neutral_amino_acid_transporter_3-Substrate,negative
55,C#C[C@]1(O)CC[C@H]2[C@@H]3CCC4=CC(=O)CC[C@@H]4[C@H]3CC[C@@]21CC,Levonorgestrel,19A-Inhibitor,negative
56,CC[C@H]1OC(=O)[C@H](C)C(=O)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@H]2N(CCCCn3cnc(-c4cccnc4)c3)C(=O)O[C@]12C,Telithromycin,Solute_carrier_organic_anion_transporter_family_member_1B3-Inhibitor,negative
57,NCc1ccc(C(=O)O)cc1,Aminomethylbenzoic Acid,Solute_carrier_family_15_member_1-Inhibitor,negative
58,O=C(O)C[C@H](O)C[C@H](O)/C=C/c1c(C2CC2)nc2ccccc2c1-c1ccc(F)cc1,Pitavastatin,UGT-Inhibitor,negative
59,CCN(CCO)CCC[C@@H](C)Nc1ccnc2cc(Cl)ccc12,Hydroxychloroquine,2D6-Inhibitor,negative
60,N#Cc1ccc(C(c2ccc(C#N)cc2)n2cncn2)cc1,Letrozole,19A-Inhibitor,negative
61,CNCC[C@@H](Oc1ccc(C(F)(F)F)cc1)c1ccccc1,Fluoxetine,2E1-Substrate,negative
62,CCCCCCNC(=N)NC(=N)N.Cl,Polihexanide,GST-Inhibitor,negative
63,COc1ccc(CC(C)N)cc1,4_methoxy_amphetamine,2D6-Substrate,negative
64,CCCCCCCC/C=C\CCCCCCCC(=O)O,oleic_acid,2E1-Substrate,negative
65,C[C@@H]1O[C@@H](OC[C@H]2O[C@@H](Oc3c(-c4ccc(O)c(O)c4)oc4cc(O)cc(O)c4c3=O)[C@H](O)[C@@H](O)[C@@H]2O)[C@H](O)[C@H](O)[C@H]1O,Rutoside,2D6-Inhibitor,negative
66,Cc1cc(CC(=O)O)n(C)c1C(=O)c1ccc(Cl)cc1,Zomepirac,3A4-Substrate,negative
67,COc1ccc(C(c2ccc(O)c(O)c2)C(Cl)(Cl)Cl)cc1,catechol_methoxychlor,2D6-Substrate,negative
68,CC(CO)Oc1ccc2c(=O)c(-c3ccccc3)coc2c1,ipriflavone_M4,1A2-Substrate,negative
69,CO[C@@H]1[C@@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](OC(=O)CC(C)C)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@@H](CC=O)C[C@@H](C)[C@@H](O)C=CC=CC[C@@H](C)OC(=O)C[C@H]1OC(C)=O,Josamycin,-,negative
70,COc1ccc(C(=O)Nc2ccccc2[C@H](C)CN2CCCCC2)cc1,Encainide,2D6-Substrate,negative
71,CCCNC[C@@H](O)COc1ccccc1C(=O)CCc1ccccc1,Propafenone,2D6-Inhibitor,negative
72,Cc1c(O)cc2c(c1C)O[C@](C)(CCC[C@H](C)CCC[C@H](C)CCCC(C)C)CC2,Tocopherol (vit E),2E1-Inhibitor,negative
73,O=[N+]([O-])O[C@@H]1CO[C@@H]2[C@@H](O)CO[C@H]12,Isosorbide Mononitrate,3A4-Substrate,negative
74,CCc1c(C)[nH]c2c1C(=O)C(CN1CCOCC1)CC2,Molindone,2D6-Substrate,negative
75,CCC(=O)N(c1ccccc1)C1CCN(CCc2ccccc2)CC1,Fentanyl,P450_HFLA-Substrate,negative
76,CN1CCC[C@H](n2nc(Cc3ccc(Cl)cc3)c3ccccc3c2=O)CC1,Azelastine,2E1-Inhibitor,negative
77,CN(C)c1ccc([C@H]2C[C@]3(C)[C@@H](CC[C@]3(O)CCCO)[C@@H]3CCC4=CC(=O)CCC4=C32)cc1,onapristone,3A4-Substrate,negative
78,CNCCCC1c2ccccc2C=Cc2ccccc21,Protriptyline,2D6-Substrate,negative
79,C[C@]12CC(=O)[C@H]3[C@@H](CCC4=CC(=O)C=C[C@@]43C)[C@@H]1CC[C@]2(O)C(=O)CO,Prednisone,-,negative
80,CCCCNc1cc(C(=O)O)cc(S(N)(=O)=O)c1Oc1ccccc1,Bumetanide,Solute_carrier_family_12_member_2-Inhibitor,negative
81,COc1cc2c(cc1OC)C(=O)[C@H](CC1CCN(Cc3ccccc3)CC1)C2,Donepezil,2D6-Substrate,negative
82,CC(C)NC(=N)NC(=N)Nc1ccc(Cl)cc1,Proguanil,2E1-Substrate,negative
83,CCCCOc1ccc2ccc(=O)oc2c1,7_butoxy_coumarin,3A4-Substrate,negative
84,CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](NC(=O)[C@@H]3C[C@@H]4c5cccc6[nH]cc(c56)C[C@H]4N(C)C3)(C(C)C)C(=O)N12,Ergoloid Mesylates,Solute_carrier_organic_anion_transporter_family_member_2B1-Inhibitor,negative
85,CCN1CCN(C(=O)N[C@@H](C(=O)N[C@@H]2C(=O)N3C(C(=O)O)=C(CSc4nnnn4C)CS[C@H]23)c2ccc(O)cc2)C(=O)C1=O,Cefoperazone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
86,CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1,Loratadine,2D6-Inhibitor,negative
87,CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)[C@H]1c1ccccc1Cl,Amlodipine,P450_HFLA-Substrate,negative
88,C#C[C@]1(O)CC[C@H]2[C@H]3[C@H](CC[C@@]21C)C1=C(CC(=O)CC1)C[C@H]3C,Tibolone,19A-Inhibitor,negative
89,Cc1cc2nc3c(=O)[nH]c(=O)nc-3n(C[C@@H](O)[C@@H](O)[C@@H](O)CO)c2cc1C,Riboflavin (vit B2),ATP_binding_cassette_sub_family_G_member_2-Substrate,negative
90,O=N[O-],Sodium Nitrite,GST-Inhibitor,negative
91,COC(=O)C1C(O)CCC2CN3CCc4c([nH]c5ccccc45)C3CC21,Yohimbine,2D6-Substrate,negative
92,OCc1cc([C@@H](O)CNCCCCCCOCCCCc2ccccc2)ccc1O,Salmeterol,P450_HFLA-Substrate,negative
93,CC1(C)S[C@@H]2[C@H](NC(=O)Cc3ccccc3)C(=O)N2[C@H]1C(=O)O,Benzylpenicillin,Canalicular_multispecific_organic_anion_transporter_1-Inducer,negative
94,CC1=C(C(=O)O)N2C(=O)[C@@H](NC(=O)[C@H](N)c3ccc(O)cc3)[C@H]2SC1,Cefadroxil,Solute_carrier_family_15_member_2-Substrate,negative
95,CNC(=C[N+](=O)[O-])NCCSCc1ccc(CN(C)C)o1,Ranitidine,2D6-Substrate,negative
96,CCC(=O)NS(=O)(=O)c1ccc(-c2c(-c3ccccc3)noc2C)cc1,Parecoxib,2D6-Inhibitor,negative
97,CC[C@H](C)[C@H](NC(=O)CN)C(=O)N[C@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H]1CSSC[C@@H]2NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CSSC[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc3cnc[nH]3)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)Cc3ccccc3)C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc3cnc[nH]3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](Cc3ccc(O)cc3)C(=O)N[C@H](C(=O)N3CCC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)O)[C@@H](C)O)[C@@H](C)O)CSSC[C@@H](C(=O)N[C@@H](CC(N)=O)C(=O)O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](Cc3ccc(O)cc3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC2=O)NC1=O)C(C)C,Insulin (human),Steroid_17_alpha_monooxygenase_Steroid_17_alpha_hydroxylase1720_lyase-Inducer,negative
98,C[n+]1c2cc(N)ccc2cc2ccc(N)cc21.Cl.Nc1ccc2cc3ccc(N)cc3nc2c1.[Cl-],Acriflavinium Chloride,1B1-Inducer,negative
99,O=[N+]([O-])c1cncn1CCN1CCOCC1,Nimorazole,-,negative
100,CNC(=O)Oc1cc(C)c(SC)c(C)c1,Methiocarb,2D6-Substrate,negative
101,COc1ccc2c(c1)Oc1cc(O)ccc1C21OC(=O)c2ccccc21,3_O_methyl_fluorescein,2C19-Substrate,negative
102,COC1=C[C@@H](C)[C@@H]2C[C@@H]3OC(=O)C[C@H]4C(C)=C(OC)C(=O)[C@H]([C@@]2(C)C1=O)[C@]34C,Quassia,1A1-Inhibitor,negative
103,CC(=O)[C@@]1(O)CC[C@H]2[C@@H]3C=C(Cl)C4=CC(=O)CC[C@]4(C)[C@H]3CC[C@@]21C,Chlormadinone,-,negative
104,C[C@]12CC[C@H]3[C@@H](CCC4=C(O)C(=O)CC[C@@]43C)[C@@H]1CCC2=O,Formestane,19A-Inhibitor,negative
105,CCCCc1ncc(C=C(Cc2cccs2)C(=O)O)n1Cc1ccc(C(=O)O)cc1,Eprosartan,-,negative
106,CCCCCc1cc(O)c2c(c1)OC(C)(C)[C@@H]1CCC(C)=C[C@@H]21,Dronabinol,-,negative
107,CON=C(C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(CSc3nc(=O)c(O)nn3C)CS[C@H]12)c1csc(N)n1,Ceftriaxone,Solute_carrier_organic_anion_transporter_family_member_1B3-Substrate,negative
108,O=[N+]([O-])OC1COC2C(O[N+](=O)[O-])COC12,Isosorbide dinitrate,-,negative
109,c1ccc2c(c1)ccc1nc3ccc4ccccc4c3cc12,dibenzacridine,1A2-Substrate,negative
110,O=C1C=C2CN(C(C(=O)C3CC3)c3ccccc3F)CCC2S1,R_95913,2D6-Substrate,negative
111,CCOc1ccc2c(Cl)cc(=O)oc2c1,4_chloro_7_ethoxycoumarin,2C19-Substrate,negative
112,COc1ccc2c(c1)c(CC(=O)NCCc1ccccc1)c(C)n2C(=O)c1ccc(Cl)cc1,indomethacin_phenethylamide,2D6-Substrate,negative
113,Cc1cccc(CN2CCN([C@@H](c3ccccc3)c3ccc(Cl)cc3)CC2)c1,Meclozin,1A2-Inhibitor,negative
114,Cc1c(OCC(F)(F)F)ccnc1C[S@@](=O)c1nc2ccccc2[nH]1,lansoprazole_R,2C19-Substrate,negative
115,NNC(=O)c1ccncc1,Isoniazid,2E1-Inducer,negative
116,COCC[C@H]1CC2CN3CCc4c([nH]c5ccccc45)[C@](C(=O)OC)(C2)C13,18_methoxy_coronaridine,2D6-Substrate,negative
117,CCC(C)(C)NCC(O)COc1ccccc1C(=O)CCc1ccccc1,Diprafenone,2D6-Substrate,negative
118,O=C(O)c1ccccc1Nc1cccc(C(F)(F)F)c1,Flufenamic Acid,2E1-Inducer,negative
119,COC(=O)[C@H](c1ccccc1)[C@H]1CCCCN1,Methylphenidate,-,negative
120,O=c1ccc2nc3ccc(OCc4ccccc4)cc3oc-2c1,benzyl_oxy_resorufin,2D6-Substrate,negative
121,CCC(=O)O[C@@H]1CC(=O)O[C@H](C)C/C=C/C=C/[C@H](OC(C)=O)[C@H](C)C[C@H](CC=O)[C@H](O[C@@H]2O[C@H](C)[C@@H](O[C@H]3C[C@@](C)(O)[C@@H](O)[C@H](C)O3)[C@H](N(C)C)[C@H]2O)[C@H]1OC,miocamycin_Mb2,3A4-Substrate,negative
122,COc1ccc(C(c2ccc(O)cc2)C(Cl)(Cl)Cl)cc1,mono_OH_methoxychlor,2E1-Substrate,negative
123,CCCCCCCCCCCCCCCCCC(=O)O,stearic_acid,2E1-Substrate,negative
124,CC[C@H]1CN2CCc3cc(OC)c(OC)cc3[C@@H]2C[C@@H]1C[C@H]1NCCc2cc(OC)c(OC)cc21,Emetine,2D6-Substrate,negative
125,CN1C[C@H](C(=O)N[C@]2(C)O[C@@]3(O)[C@@H]4CCCN4C(=O)[C@H](Cc4ccccc4)N3C2=O)C=C2c3cccc4[nH]cc(c34)C[C@H]21,Ergotamine,-,negative
126,O=c1cc(-c2ccc(O)cc2)oc2cc(O)cc(O)c12,apigenin,1A2-Substrate,negative
127,CN1CCC23CCCCC2C1Cc1ccc(O)cc13,Dextrorphan,2D6-Substrate,negative
128,COCc1c(C(=O)OC(C)C)ncc2[nH]c3ccc(OCc4ccccc4)cc3c12,Abecarnil,-,negative
129,CN1CCCN=C1C=Cc1cccs1,Pyrantel,2D6-Substrate,negative
130,C[C@H]1O[C@H](O[C@@H]2[C@@H](CO)O[C@H](O[C@@H]3[C@@H](CO)O[C@H](O)[C@H](O)[C@H]3O)[C@H](O)[C@H]2O)[C@H](O)[C@@H](O)[C@@H]1N[C@H]1C=C(CO)[C@@H](O)[C@H](O)[C@H]1O,Acarbose,2E1-Inducer,negative
131,CC(=O)N[C@H](CS)C(=O)O,Acetylcysteine,Multidrug_resistance_protein_1-Inducer,negative
132,Cc1cc(O)cc(C)c1Cl,Chloroxylenol,2E1-Substrate,negative
133,Cn1c(N)nc2ncc(-c3ccccc3)cc21,2_amino_1_methyl_6_phenylimidazo_4_5_b_pyridine,1A2-Substrate,negative
134,Cc1cccc(C)c1NC(=O)[C@H](C)N,Tocainide,-,negative
135,Clc1ccc(Cl)c(-c2cc(Cl)c(Cl)cc2Cl)c1,PCB_101,3A4-Substrate,negative
136,CCC[C@@H]1C[C@@H](C(=O)N[C@H]([C@H](C)Cl)[C@H]2O[C@H](SC)[C@H](O)[C@@H](O)[C@H]2O)N(C)C1,Clindamycin,-,negative
137,CCCCCOc1ccc2ccc(=O)oc2c1,7_pentoxy_coumarin,3A4-Substrate,negative
138,CCCCN(C)N=O,NN_methyl_butyl_nitrosoamine,2E1-Substrate,negative
139,CNC(=NC#N)NCCSCc1nc[nH]c1C,Cimetidine,P450_HFLA-Inhibitor,positive
140,CCCCCCCCCCCCCCCC(=O)O,palmitic_acid,2E1-Substrate,negative
141,C[C@H](N)Cc1ccccc1,Dexamfetamine,2D6-Inhibitor,negative
142,O=C(c1cccs1)c1ccc(OCc2nnn[nH]2)c(Cl)c1Cl,tienilic_acid_newderiv_9,2C9-Substrate,negative
143,CCC(=O)C(C[C@@H](C)N(C)C)(c1ccccc1)c1ccccc1,methadone_R,2D6-Substrate,negative
144,CN1CCN(C(=O)NC(Cc2ccccc2)C(=O)NC(C=CS(=O)(=O)c2ccccc2)CCc2ccccc2)CC1,K11777,2E1-Substrate,negative
145,CC(C)[C@H](NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@@H](Cc1cnc[nH]1)C(=O)N1CCC[C@@H]1C(=O)N[C@@H](Cc1ccccc1)C(=O)O,Angiotensinamide,Methyltransferase-Inducer,negative
146,CCOc1ccccc1OCCN[C@H](C)Cc1ccc(OC)c(S(N)(=O)=O)c1,Tamsulosin,2D6-Substrate,negative
147,CC(C)(C)NC[C@H](O)COc1nsnc1N1CCOCC1,Timolol,2D6-Substrate,negative
148,CN1C(=O)NC(=O)[C@@](C)(C2=CCCCC2)C1=O,hexobarbital_R,2C19-Substrate,negative
149,Cc1ccc(C)c(OCCCC(C)(C)C(=O)O)c1,Gemfibrozil,Solute_carrier_organic_anion_transporter_family_member_1B1-Inhibitor,negative
150,Cc1cn([C@H]2C[C@H](N=[N+]=[N-])[C@@H](CO)O2)c(=O)[nH]c1=O,Zidovudine,-,negative
151,c1ccc2[nH]c(-c3cscn3)nc2c1,Tiabendazole,-,negative
152,Oc1cc(Cl)ccc1Oc1ccc(Cl)cc1Cl,Triclosan,SUL-Inhibitor,negative
153,O[C@@](CCN1CCCCC1)(c1ccccc1)[C@@H]1C[C@@H]2C=C[C@H]1C2,Biperiden,2D6-Inhibitor,negative
154,Cc1cccc(C)c1OC[C@H](C)N,Mexiletine,2E1-Substrate,negative
155,Cc1ccccc1,toluene,2E1-Substrate,negative
156,CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1,Vinblastine,2D6-Substrate,negative
157,CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1,Oseltamivir,Solute_carrier_family_15_member_1-Substrate,negative
158,N=C(NCCCCCCNC(=N)NC(=N)Nc1ccc(Cl)cc1)NC(=N)Nc1ccc(Cl)cc1,Chlorhexidine,Methyltransferase-Inhibitor,negative
159,CC(Nc1cc(-c2[nH]c(S(C)=O)nc2-c2ccc(F)cc2)ccn1)c1ccccc1,ML_3603,2D6-Substrate,negative
160,CC(=O)Nc1nnc(S(N)(=O)=O)s1,Acetazolamide,-,negative
161,COc1ccc(-c2cc(=O)c3c(OC)c(OC)c(OC)c(OC)c3o2)cc1,tangeretin,2D6-Substrate,negative
162,NN=c1[nH]ncc2ccccc12,Hydralazine,Methyltransferase-Inducer,negative
163,N[C@@H](C(=O)N[C@@H]1C(=O)N2C(C(=O)O)=C(Cl)CS[C@H]12)c1ccccc1,Cefaclor,Solute_carrier_family_22_member_6-Inhibitor,negative
164,CC(=O)O[C@H](CC(=O)[O-])C[N+](C)(C)C,Acetylcarnitine,Solute_carrier_family_22_member_5-Substrate,negative
165,NC(N)=Nc1nc(CSCCN=CNS(=O)(=O)c2ccc(Br)cc2)cs1,Ebrotidine,-,negative
166,CN[C@@]1(c2ccccc2Cl)CCCCC1=O,Ketamine,2D6-Substrate,negative
167,O=C(O)[C@H](CC(=O)N1C[C@H]2CCCC[C@H]2C1)Cc1ccccc1,Mitiglinide,UGT-Substrate,negative
168,C[C@H](CCC(=O)O)[C@H]1CC[C@H]2[C@H]3[C@H](CC[C@@]21C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,Chenodeoxycholic Acid,GST-Inhibitor,negative
169,Cc1ccc(S(=O)(=O)N(C)c2ccnn2-c2ccccc2)cc1,DMZ,2C19-Substrate,negative
170,Nc1nc2ccc(OC(F)(F)F)cc2s1,Riluzole,-,negative
171,CC(C)C[C@H](NC(=O)[C@@H](Cc1ccccc1)NC(=O)c1cnccn1)B(O)O,Bortezomib,2D6-Inhibitor,negative
172,C[C@H](C(=O)O)c1ccc(C(=O)c2cccs2)cc1,Suprofen,-,negative
173,Cc1ccc(-c2nc3ccc(C)cn3c2CC(=O)N(C)C)cc1,Zolpidem,P450_HFLA-Substrate,negative
174,CN(C)CCCN1c2ccccc2Sc2ccc(Cl)cc21,Chlorpromazine,2E1-Inhibitor,negative
175,C=Cc1ccccc1,styrene,2E1-Substrate,negative
176,CC(C)C(C)NCC(O)COc1cccc2ccccc12,isopropyl_propranolol,2D6-Substrate,negative
177,COc1cc(N)c(Cl)cc1C(=O)N[C@@H]1CCN(CCCOc2ccc(F)cc2)C[C@@H]1OC,cisapride,2C8-Substrate,negative
178,Oc1ccc(O)cc1,Hydroquinone,3A4-Substrate,negative
179,C[C@@H]1O[C@@H](O[C@H]2C[C@@H](O)[C@]3(CO)[C@@H]4[C@H](CC[C@]3(O)C2)[C@@]2(O)CC[C@H](C3=CC(=O)OC3)[C@@]2(C)C[C@H]4O)[C@H](O)[C@H](O)[C@H]1O,G-strophanthin,Multidrug_resistance_associated_protein_1-Inducer,negative
180,O=c1cc(C(F)(F)F)c2ccc(OCc3ccccc3)cc2o1,7_benzyloxy_4_trifluoromethyl_coumarin,2C19-Substrate,negative
181,Cn1cc[nH]c1=S,Thiamazole,2E1-Inhibitor,negative
182,c1ccc(-c2ccc([C@H](c3ccccc3)n3ccnc3)cc2)cc1,Bifonazole,19A-Inhibitor,negative
183,COc1ccc(O)cc1,Mequinol,GST-Inducer,negative
184,CN1CCN(C(c2ccccc2)c2ccccc2)CC1,Cyclizine,2C9-Inhibitor,negative
185,O=S(=O)([O-])[O-],Sodium Sulfate,P450_HP-Inducer,negative
186,N[C@@H]1CONC1=O,Cycloserine,Proton_coupled_amino_acid_transporter_1-Substrate,negative
187,O=C(O)C=Cc1ccccc1,Bemiparin,SUL-Substrate,negative
188,O=S(=O)([O-])[S-],Thiosulfate,2E1-Inhibitor,negative
189,Cc1nc(C)c2c(n1)N(Cc1ccc(-c3ccccc3-c3nnn[nH]3)cc1)C(=O)CC2,Tasosartan,-,negative
190,C[C@H](CCC(=O)O)[C@@H]1CC[C@H]2[C@H]3[C@H](CC[C@]12C)[C@@]1(C)CC[C@@H](O)C[C@H]1C[C@H]3O,chenodeoxycholic_acid,3A4-Substrate,negative
191,N=C(N)NC(=N)NCCc1ccccc1,Phenformin,2D6-Substrate,negative
192,CC(Cc1ccccc1)(NC(=O)CN)c1ccccc1,Remacemide,-,negative
193,Oc1ccccc1-c1ccccc1,O_phenylphenol,2E1-Substrate,negative
194,N[C@@H](Cc1cc(I)c(Oc2cc(I)c(O)c(I)c2)c(I)c1)C(=O)O,Levothyroxine Sodium,3A4-Substrate,negative
195,c1cnc(N2CCNCC2)nc1,1_PP,2D6-Substrate,negative
196,CCC1=C[C@@H]2CN(C1)Cc1c([nH]c3ccccc13)[C@@](C(=O)OC)(c1cc3c(cc1OC)N(C)[C@H]1[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]4(CC)C=CCN5CC[C@]31[C@@H]54)C2,Vinorelbine,2D6-Substrate,negative
197,Cn1c(N)nc2c3cccnc3ccc21,2_amino_3_methylimidazo_4_5_f_quinoline,1A2-Substrate,negative
198,CCN(CC)CCS(=O)(=O)C1CCN2C(=O)c3coc(n3)CC(=O)CC(O)C=C(C)C=CCNC(=O)C=CC(C)C(C(C)C)OC(=O)C12,Dalfopristin,-,negative
199,N#Cc1ccc(C2CCCc3cncn32)cc1,Fadrozole,-,negative
200,CCCCCCCCCCCCCC(=O)O,myristic_acid,2E1-Substrate,negative
201,O=C(c1cccs1)c1ccc(O)c(Cl)c1Cl,tienilic_acid_deriv_1,2C9-Substrate,negative
202,CCCN(CCC)N=O,NN_dipropyl_nitrosoamine,2E1-Substrate,negative
203,COC(=O)C1=C(C)NC(C)=C(C(=O)OCC(C)=O)C1c1ccccc1[N+](=O)[O-],Aranidipine,-,negative
204,N.N.O=C1O[Pt]OC(=O)C12CCC2,Carboplatin,3A4-Inducer,negative
205,Cc1noc(NS(=O)(=O)c2ccc(N)cc2)c1C,Sulfafurazole,-,negative
206,CO[C@@H]1C[C@H](O[C@@H]2[C@@H](C)C(=O)O[C@H](C)[C@H](C)[C@H](O)[C@@H](C)C(=O)[C@@]3(CO3)C[C@H](C)[C@H](O[C@H]3O[C@@H](C)C[C@@H](N(C)C)[C@H]3O)[C@H]2C)O[C@@H](C)[C@H]1O,Oleandomycin,UGT-Substrate,negative
207,CCC1(c2ccccc2)C(=O)NC(=O)NC1=O,Phenobarbital,4A11-Inducer,negative
208,Cc1c(OCC(F)(F)F)ccnc1CS(=O)c1nc2ccccc2[nH]1,Lansoprazole,4A11-Inducer,negative
209,C[C@@H]1NC(=O)[C@H](NC(=O)c2ncccc2O)[C@H](C)OC(=O)[C@@H](c2ccccc2)NC(=O)[C@H]2CC(=O)CCN2C(=O)[C@H](Cc2ccc(N(C)C)cc2)N(C)C(=O)[C@H]2CCCN2C1=O,Virginiamycin,Methyltransferase-Inhibitor,negative
210,COc1cc2c(c(OC)c1OC)-c1c(cc(OC)c(OC)c1OC)C[C@@H](C)[C@@H](C)C2,deoxy_schizandrin,3A4-Substrate,negative
211,Clc1cccc(N2CCNCC2)c1,m-Chlorophenylpiperazine,2D6-Substrate,negative
212,O=[S@](Cc1cc(OCC2CC2)ccn1)c1nc2ccc(F)cc2[nH]1,H_259_31_R,2C19-Substrate,negative
213,CC[C@H](OC(C)=O)C(C[C@H](C)NC)(c1ccccc1)c1ccccc1,norLAAM,2D6-Substrate,negative
214,C[C@@H](O)C(=O)O,Milchs√§ure,Monocarboxylate_transporter_1-Substrate,negative
215,CCNc1nc(Cl)nc(NC(C)(C)C)n1,terbutylazine,2C19-Substrate,negative
216,NC1=NC[C@@H]2c3ccccc3Cc3ccccc3N12,Epinastine,2D6-Inhibitor,negative
217,CN(C)CCN(Cc1ccccc1)c1ccccn1,Tripelennamine,2D6-Inhibitor,negative
218,CC(C)CC(O)NC(=O)[C@H](Cc1ccccc1)NC(=O)c1cnccn1,bortezomib_M1_M2,2C19-Substrate,negative
219,CC1=CC[C@H]2[C@@H](C1)C2(C)C,delta_3_carene,2D6-Substrate,negative
220,NS(=O)(=O)c1cc2c(cc1Cl)N=CNS2(=O)=O,Chlorothiazide,Solute_carrier_family_22_member_8-Substrate,negative
221,Nc1nc2[nH]cnc2c(=S)[nH]1,Tioguanine,Solute_carrier_family_28_member_3-Substrate,negative
222,CC=CCC(C)C(=O)C1C(=O)NC(C(C)C)C(=O)N(C)CC(=O)N(C)C(CC(C)C)C(=O)NC(C(C)C)C(=O)N(C)C(CC(C)C)C(=O)NC(C)C(=O)NC(C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(CC(C)C)C(=O)N(C)C(C(C)C)C(=O)N1C,Valspodar,-,negative
223,CC(C)(C#N)c1cc(Cn2cncn2)cc(C(C)(C)C#N)c1,Anastrozole,19A-Inhibitor,negative
224,CCC(=O)O[C@H]1[C@H](C)O[C@@H](O[C@@H]2[C@@H](C)O[C@@H](O[C@@H]3[C@@H](OC)[C@H](OC(=O)CC)CC(=O)O[C@H](C)CC=CC=C[C@H](OC(C)=O)[C@H](C)C[C@@H]3CC=O)[C@H](O)[C@H]2N(C)C)C[C@@]1(C)OC(C)=O,Miocamycin,3A4-Inhibitor,negative
225,NC(=O)C1(N2CCCCC2)CCN(CCCC(=O)c2ccc(F)cc2)CC1,Pipamperone,GST-Inducer,negative
226,CCN[C@@H](C)Cc1cccc(C(F)(F)F)c1,Dexfenfluramine,2E1-Inhibitor,negative
227,COc1ncnc(NS(=O)(=O)c2ccc(N)cc2)c1OC,Sulfadoxine,-,negative
228,COc1cccc2c1C(=O)c1c(O)c3c(c(O)c1C2=O)C[C@@](O)(C(C)=O)C[C@@H]3O[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1,Daunorubicin,-,negative
